Triple GLP-1 / GIP / Glucagon Agonist — 10mg/vial
$160.00 AUD
First-in-class triple agonist — TRIUMPH-2 trial: up to 24.2% weight reduction.
🏆 AU$39 cheaper than the closest competitor*
*Peptide Lab, 10mg/vial: $199. E42: $160. Verified April 2026.
💧 Need BAC water? 30mL bacteriostatic water available — $21.90 ($13 less than AU competitors). Add to your order.
Retatrutide is a first-in-class triple agonist peptide targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Developed by Eli Lilly, the TRIUMPH-2 Phase 2 clinical trial demonstrated unprecedented mean body weight reductions of up to 24.2% at 48 weeks at the highest dose — the most significant pharmacologically-induced weight reduction at the time of reporting.
Its unique triple mechanism represents the next frontier beyond dual GIP/GLP-1 agonists like tirzepatide, adding glucagon receptor agonism for increased energy expenditure. At Element42, we provide Retatrutide at verified purity of 99.315% (third-party HPLC tested by Janoshik Analytical).
"FOR RESEARCH USE ONLY. This information is provided for scientific and educational purposes only. It does not constitute medical advice or a recommendation for human use."
| Compound | Retatrutide |
| Form | Lyophilized powder |
| Dosage | 10mg/vial |
| Purity | 99.315% (HPLC verified) |
| Testing | Janoshik Analytical — HPLC + MS |
| COA Date | 10 Jul 2025 |
| Storage | 2-8°C (refrigerated) |
| Origin | GMP facility |
Retatrutide acts as a balanced triple agonist at the GLP-1 receptor (GLP1R), GIP receptor (GIPR), and glucagon receptor (GCGR). GLP1R and GIPR activation drives synergistic insulin secretion, appetite suppression, and slowed gastric emptying — similar to tirzepatide.
The additional glucagon receptor agonism increases hepatic energy expenditure, promotes lipolysis and fatty acid oxidation, and may reduce hepatic steatosis. This triple mechanism provides metabolic benefits exceeding those of dual GIP/GLP-1 agonism alone. The peptide contains a fatty acid modification conferring extended half-life for once-weekly dosing in clinical protocols.
Verified 99.315% purity by Janoshik Analytical. COA published on site with batch details.
Based in Australia with express shipping nationwide. Discreet, temperature-controlled packaging.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site with full batch details.
Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism, making it a triple agonist. The glucagon component increases energy expenditure and lipolysis, which is why TRIUMPH-2 showed up to 24.2% weight reduction versus tirzepatide's ~20-22%. This triple mechanism represents the next generation of incretin-based metabolic research.
Subcutaneous injection once weekly. The TRIUMPH-2 protocol used a dose escalation schedule: starting at 0.5 mg/week, escalating through 1, 2, 4, 8 mg to a target dose of 12 mg/week over 24 weeks. The fatty acid modification provides the extended half-life that enables weekly dosing.
Our batch was tested at 99.315% purity by Janoshik Analytical (COA dated 10 Jul 2025). Full HPLC and mass spectrometry results are available on our Lab Results page.
Retatrutide is legal to purchase for legitimate research purposes in Australia. It is not a scheduled substance when intended for laboratory research use only. All sales are strictly for research purposes — not for human or veterinary consumption.
Enter your email and we'll alert you the moment it's back in stock.